Table 2.
Changes in the “off” medications UPDRS III and UPDRS II scores.
| Score (Range) | Measures | Preoperative | One Year | Δ Change | % | ^ p |
|---|---|---|---|---|---|---|
| UPDRSIII “off” (0–108) | Mean ± SD | 40.0 ± 12.4 | 19.7 ± 7.1 | −20.3 ± 8.9 | 49.3% | <0.001 * |
| Median (IQR) | 36.3 (31.3–54.0) | 18.0 (13.4–26.8) | −19.5 (−26.0–−16.3) | |||
| Range | 20.0–59.0 | 9.0–33.0 | −36.0–2.0 | |||
| Tremors “off” (0–28) | Mean ± SD | 9.8 ± 6.9 | 1.8 ± 1.7 | −8.0 ± 5.9 | 81.6% | <0.001 * |
| Median (IQR) | 10.0 (3.0–16.8) | 1.3 (0.0–3.0) | −7.5 (−14.4–−3.0) | |||
| Range | 0.0–19.0 | 0.0–5.0 | −17.0–0.0 | |||
| Rigidity “off” (0–20) | Mean ± SD | 7.0 ± 3.4 | 3.5 ± 2.4 | −3.5±2.1 | 50.0% | <0.001 * |
| Median (IQR) | 8.0 (4.0–9.8) | 3.3 (2.0–5.0) | −3.0 (−4.9–−2.0) | |||
| Range | 1.0–12.0 | 0.0–10.0 | −9.0–−1.0 | |||
| Bradykinesia “off” (0–32) | Mean ± SD | 14.5 ± 4.4 | 8.8 ± 3.4 | −5.7±2.7 | 39.3% | <0.001 * |
| Median (IQR) | 14.0 (12.0–17.8) | 7.8 (6.3–11.8) | −6.0 (−7.8–−4.5) | |||
| Range | 7.5–23.0 | 5.0–16.0 | −9.5–2.0 | |||
| Axial “off” (0–16) | Mean ± SD | 5.2 ± 1.3 | 3.3 ± 1.5 | −2.0 ± 1.2 | 38.5% | <0.001 * |
| Median (IQR) | 5.3 (4.3–6.0) | 3.0 (2.1–3.9) | −2.0 (−2.5–−1.6) | |||
| Range | 3.0–7.0 | 1.5–8.0 | −3.5–2.5 | |||
| UPDRSII “off” (0–52) | Mean ± SD | 20.1 ± 4.2 | 11.2 ± 6.4 | −8.8 ± 4.5 | 73.8% | <0.001 * |
| Median (IQR) | 21.0 (16.0–23.0) | 10.5 (7.3–13.0) | −9.5 (−12.0–−8.0) | |||
| Range | 13.0–27.0 | 5.0–35.0 | −13.0–8.0 |
Total = 20; Δ Change from before to after (negative values indicate a reduction); p probability (p-value); SD standard deviation; UPDRS Unified Parkinson’s Disease Rating Scale; % percentage of change; ^ Wilcoxon Signed Ranks Test; * Significant.